Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05CWG
|
|||
| Former ID |
DNC001418
|
|||
| Drug Name |
TEI-8362
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C26H28N4O9
|
|||
| Canonical SMILES |
CC1=CC(=CC2=C1C(=O)OC(=N2)NCCCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)OCC3=CC=CC=C3
|
|||
| InChI |
1S/C26H28N4O9/c1-15-12-17(13-19-22(15)24(36)39-25(29-19)27-11-5-8-20(31)32)28-23(35)18(9-10-21(33)34)30-26(37)38-14-16-6-3-2-4-7-16/h2-4,6-7,12-13,18H,5,8-11,14H2,1H3,(H,27,29)(H,28,35)(H,30,37)(H,31,32)(H,33,34)/t18-/m0/s1
|
|||
| InChIKey |
JLDVWXAMNKPCJI-SFHVURJKSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| SuperDrug ATC ID |
Telapre
|
|||
| SuperDrug CAS ID |
cas=059803984
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.